The pancreas allograft donor: Current status, controversies, and challenges for the future

Clinical Transplantation

Volumn 24, Issue 4, 2010, Pages 433-449

  Fridell, Jonathan A ^a   Rogers, Jeffrey ^b   Stratta, Robert J ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Body mass index; Brain death; Donation after cardiac death; Donor age; Extended donors; Kidney pancreas transplantation; Organ procurement; Pancreas transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; C PEPTIDE; DESMOPRESSIN; DEXAMETHASONE; HEMOGLOBIN A1C; HEPATITIS B CORE ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN M; INSULIN; LEVOTHYROXINE; LIOTHYRONINE; METHYLPREDNISOLONE; THYROID HORMONE; VASOPRESSIN;

ACIDOSIS; AUTONOMIC DYSFUNCTION; BACTEREMIA; BLOOD CLOTTING DISORDER; BLOOD GLUCOSE MONITORING; BRAIN DEATH; BRAIN TUMOR; CADAVER DONOR; CAUSE OF DEATH; CLINICAL EVALUATION; COLD ISCHEMIA; DIABETES INSIPIDUS; DISEASE TRANSMISSION; DISSEMINATED INTRAVASCULAR CLOTTING; DIURESIS; ERYTHROCYTE CONCENTRATE; FLUID RESUSCITATION; HEART ARRHYTHMIA; HEMATOCRIT; HEMODYNAMICS; HEPATITIS C; HLA SYSTEM; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHERMIA; INFECTION RISK; KIDNEY PANCREAS TRANSPLANTATION; OBESITY; ORGAN DONOR; ORGAN PRESERVATION; PANCREAS ALLOGRAFT; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SKIN CANCER; TREATMENT CONTRAINDICATION; VASODILATATION;

GRAFT SURVIVAL; HUMANS; PANCREAS TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955765039     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01253.x     Document Type: Review

References (89)

1. Tuttle-Newhall JE, Krishnan SM, Levy MF, McBride V, Orlowski JP, Sung RS. Organ donation and utilization in the United States: 1998-2007. Am J Transplant 2009, 9(4 Pt 2).
2. McCullough KP, Keith DS, Meyer KH, Stock PG, Brayman KL, Leichtman AB. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant 2009, 9(4 Pt 2).
3. Krieger NR, Odorico JS, Heisey DM. Underutilization of pancreas donors. Transplantation 2003, 75:1271.
4. Stratta RJ, Bennett L. Pancreas underutilization in the United States: analysis of United Network for Organ Sharing data. Transplant Proc 1997, 29:3309.
5. Nygaard CE, Townsend RN, Diamond DL. Organ donor management and organ outcome: a 6-year review from a Level I trauma center. J Trauma 1990, 30:728.
6. Jenkins DH, Reilly PM, Schwab CW. Improving the approach to organ donation: a review. World J Surg 1999, 23:644.
7. Lopez-Navidad A, Caballero F. For a rational approach to the critical points of the cadaveric donation process. Transplant Proc 2001, 33.
8. Rosendale JD, Chabalewski FL, McBride MA. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002, 2:761.
9. Shivalkar B, Van Loon J, Wieland W. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993, 87:230.
10. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. N Engl J Med 2004, 351:2730.
11. Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ donor. Pediatr Clin North Am 2001, 48:715.
12. Cooper DK, Novitzky D, Wicomb WN. The pathophysiological effects of brain death on potential donor organs, with particular reference to the heart. Ann R Coll Surg Engl 1989, 71:261.
13. Novitzky D. Donor management: state of the art. Transplant Proc 1997, 29:3773.
14. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation 1988, 45:32.
15. Novitzky D, Cooper DK, Reichart B. The value of hormonal therapy in improving organ viability in the transplant donor. Transplant Proc 1987, 19(1 Pt 3).
16. Salim A, Vassiliu P, Velmahos GC. The role of thyroid hormone administration in potential organ donors. Arch Surg 2001, 136:1377.
17. Rosendale JD, Kauffman HM, McBride MA. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003, 75:1336.
18. Rosendale JD, Kauffman HM, McBride MA. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003, 75:482.
19. Gores PF, Gillingham KJ, Dunn DL, Moudry-Munns KC, Najarian JS, Sutherland DE. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. Ann Surg 1992, 215:217.
20. Hefty TR, Cotterell LW, Fraser SC, Goodnight SH, Hatch TR. Disseminated intravascular coagulation in cadaveric organ donors. Incidence and effect on renal transplantation. Transplantation 1993, 55:442.
21. Gil-Vernet S, Martinez-Brotons F, Gonzalez C, Domenech P, Carreras M. Disseminated intravascular coagulation in multiorgan donors. Transplant Proc 1992, 24:33.
22. Pastural M, Barrou B, Delcourt A, Bitker MO, Ourahma S, Richard F. Successful kidney transplantation using organs from a donor with disseminated intravascular coagulation and impaired renal function: case report and review of the literature. Nephrol Dial Transplant 2001, 16:412.
23. Kapur S, Bonham CA, Dodson SF, Dvorchik I, Corry RJ. Strategies to expand the donor pool for pancreas transplantation. Transplantation 1999, 67:284.
24. Boggi U, Del Chiaro M, Vistoli F. Pancreas transplantation from marginal donors. Transplant Proc 2004, 36:566.
25. Decraemer I, Cathenis K, Troisi R, deHemptinne B, Hesse UJ. The influence of desmopressin and vasopressors in the donor management on graft function following pancreas transplantation. Transplant Proc 2004, 36.
26. Schnuelle P, Gottmann U, Hoeger S. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009, 302:1067.
27. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000, 70.
28. Buell JF, Trofe J, Sethuraman G. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003, 76:340.
29. Kauffman HM, McBride MA, Delmonico FL. UNOS Transplant Tumor Registry: donors with a history of cancer. Transplant Proc 2001, 33.
30. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003, 9:451.
31. Freeman RB, Giatras I, Falagas ME. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999, 68.
32. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant 2005, 19:364.
33. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001, 1:185.
34. Natov SN. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 1: hepatitis B virus). Transpl Infect Dis 2002, 4:124.
35. Natov SN, Pereira BJ. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 1: hepatitis B virus). Transpl Infect Dis 2002, 4:117.
36. Sarmento A, Freitas F, Tavares AP, Machado D. Organ donor viral screening and its implications in transplantation; an overview. Transplant Proc 2000, 32.
37. Tamsma JT, Pasma GP, van der Woude FJ, Gooszen HG, Lemkes HH. Transfer of non-insulin-dependent diabetes to a pancreas transplant recipient. Lancet 1994, 343:111.
38. Sung RS, Galloway J, Tuttle-Newhall JE. Organ donation and utilization in the United States, 1997-2006. Am J Transplant 2008, 8.
39. Gruessner RW, Sutherland DE, Gruessner AC. Survival after pancreas transplantation. JAMA 2005, 293. author reply 675
40. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003, 290.
41. Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant 2004, 4.
42. Neidlinger NA, Odorico JS, Sollinger HW, Fernandez LA. Can 'extreme' pancreas donors expand the donor pool? Curr Opin Organ Transplant 2008, 13:67.
43. Ojo AO, Meier-Kriesche HU, Hanson JA. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001, 71:82.
44. Wolfe RA, McCullough KP, Schaubel DE. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant 2008, 8(4 Pt 2).
45. Young BY, Gill J, Huang E. Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol 2009, 4:845.
46. Fridell JA, Mangus RS, Hollinger EF. No difference in transplant outcomes for local and import pancreas allografts. Transplantation 2009, 88:723.
47. Stratta RJ, Farney AC, Rogers J. Import pancreas allografts: good from far or far from good? Transplantation 2009, 88:622.
48. Stegall MD, Dean PG, Sung R. The rationale for the new deceased donor pancreas allocation schema. Transplantation 2007, 83.
49. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007, 7(5 Pt 2).
50. Sutherland DE, Gruessner RW, Dunn DL. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001, 233:463.
51. Boggi U, Del Chiaro M, Signori S. Pancreas transplants from donors aged 45 years or older. Transplant Proc 2005, 37:1265.
52. Salvalaggio PR, Schnitzler MA, Abbott KC. Patient and graft survival implications of simultaneous pancreas kidney transplantation from old donors. Am J Transplant 2007, 7:1561.
53. Schenker P, Wunsch A, Ertas N. Long-term results after simultaneous pancreas-kidney transplantation using donors aged 45 years or older. Transplant Proc 2008, 40:923.
54. Singh RP, Rogers J, Farney AC. Outcomes of extended donors in pancreatic transplantation with portal-enteric drainage. Transplant Proc 2008, 40:502.
55. Humar A, Ramcharan T, Kandaswamy R, Gruessner RW, Gruessner AG, Sutherland DE. The impact of donor obesity on outcomes after cadaver pancreas transplants. Am J Transplant 2004, 4:605.
56. Humar A, Ramcharan T, Kandaswamy R, Gruessner RW, Gruessner AC, Sutherland DE. Technical failures after pancreas transplants: why grafts fail and the risk factors - a multivariate analysis. Transplantation 2004, 78.
57. Salvalaggio PR, Davies DB, Fernandez LA, Kaufman DB. Outcomes of pancreas transplantation in the United States using cardiac-death donors. Am J Transplant 2006, 6(5 Pt 1).
58. Fernandez LA, Di Carlo A, Odorico JS. Simultaneous pancreas-kidney transplantation from donation after cardiac death: successful long-term outcomes. Ann Surg 2005, 242:716.
59. Farney AC, Singh RP, Hines MH. Experience in renal and extrarenal transplantation with donation after cardiac death donors with selective use of extracorporeal support. J Am Coll Surg 2008, 206.
60. Schulz T, Schenker P, Flecken M, Kapischke M. Donors with a maximum body weight of 50 kg for simultaneous pancreas-kidney transplantation. Transplant Proc 2005, 37.
61. Fernandez LA, Turgeon NA, Odorico JS. Superior long-term results of simultaneous pancreas-kidney transplantation from pediatric donors. Am J Transplant 2004, 4.
62. Buggenhout A, Hoang AD, Hut F, Lekeufack JB, Bali MA, De Pauw L. Pediatric en bloc dual kidney-pancreas transplantation into an adult recipient: a simplified technique. Benefits of the en bloc kidney-pancreas transplantation technique in pediatric donors. Am J Transplant 2004, 4:663.
63. Vinkers MT, Rahmel AO, Slot MC, Smits JM, Schareck WD. How to recognize a suitable pancreas donor: a Eurotransplant study of preprocurement factors. Transplant Proc 2008, 40.
64. Vinkers MT, Rahmel AO, Slot MC, Smits JM, Schareck WD. Influence of a donor quality score on pancreas transplant survival in the Eurotransplant area. Transplant Proc 2008, 40.
65. Axelrod DA, Sung RS, Meyer KH, Wolfe RA, Kaufman DB. Systematic evaluation of pancreas allograft quality, outcomes, and geographic variation in utilization. Am J Transplant 2010, 10:837.
66. Vandamme JP, Bonte J. The branches of the celiac trunk. Acta Anat (Basel) 1985, 122:110.
67. Hiatt JR, Gabbay J, Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg 1994, 220:50.
68. Abu-Elmagd K, Fung J, Bueno J. Logistics and technique for procurement of intestinal, pancreatic, and hepatic grafts from the same donor. Ann Surg 2000, 232:680.
69. Nghiem DD. Revascularization of the gastroepiploic artery in pancreas transplant. Transpl Int 2008, 21:774.
70. Socci C, Orsenigo E, Zuber V. Triple arterial reconstruction improves vascularization of whole pancreas for transplantation. Transplant Proc 2006, 38.
71. Thai N, Khan A, Tom K, Basu A, Shapiro R, Fung JJ. Revascularization of the gastroduodenal artery in a pancreas allograft from a donor with a replaced right hepatic artery. Transplantation 2005, 79:503.
72. de Boer J, De Meester J, Smits JM. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int 1999, 12:447.
73. Hatano E, Kiuchi T, Tanaka A. Hepatic preservation with histidine-tryptophan-ketoglutarate solution in living-related and cadaveric liver transplantation. Clin Sci (Lond) 1997, 93:81.
74. Troisi R, Meester D, Regaert B. Physiologic and metabolic results of pancreatic cold storage with histidine-tryptophan-ketoglutarate-HTK solution (custodiol) in the porcine autotransplantation model. Transpl Int 2000, 13:98.
75. Fridell JA, Agarwal A, Milgrom ML, Goggins WC, Murdock P, Pescovitz MD. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution for organ preservation in clinical pancreas transplantation. Transplantation 2004, 77.
76. Agarwal A, Murdock P, Pescovitz MD, Goggins WC, Milgrom ML, Fridell JA. Follow-up experience using histidine-tryptophan ketoglutarate solution in clinical pancreas transplantation. Transplant Proc 2005, 37.
77. Agarwal A, Powelson JA, Goggins WC, Milgrom ML, Fridell JA. Organ preservation with histidine-tryptophan ketogluatarate solution in clinical pancreas transplantation: an update of the Indiana university experience. Transplant Proc 2008, 40:498.
78. Potdar S, Malek S, Eghtesad B. Initial experience using histidine-tryptophan-ketoglutarate solution in clinical pancreas transplantation. Clin Transplant 2004, 18:661.
79. Englesbe MJ, Moyer A, Kim DY. Early pancreas transplant outcomes with histidine-tryptophan-ketoglutarate preservation: a multicenter study. Transplantation 2006, 82:136.
80. Becker T, Ringe B, Nyibata M. Pancreas transplantation with histidine-tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution: is there a difference? JOP 2007, 8:304.
81. Alonso D, Dunn TB, Rigley T. Increased pancreatitis in allografts flushed with histidine-tryptophan-ketoglutarate solution: a cautionary tale. Am J Transplant 2008, 8.
82. Dunn TB, DelCoro C, Ferrer J. Risk factors for clinically significant graft pancreatitis - is it the solution? Am J Transplant 2008, 8(Suppl. 2).
83. Stewart ZA, Cameron AM, Singer AL, Dagher NN, Montgomery RA, Segev DL. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. Am J Transplant 2009, 9:217.
84. Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev DL. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. Am J Transplant 2009, 9:286.
85. Stewart ZA, Lonze BE, Warren DS. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. Am J Transplant 2009, 9.
86. Boggi U, Vistoli F, Del Chiaro M. Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study. Transplantation 2004, 77.
87. Codas R, Petruzzo P, Morelon E. IGL-1 solution in kidney transplantation: first multi-center study. Clin Transplant 2009, 23:337.
88. Manrique A, Jimenez C, Herrero ML. Pancreas preservation with the University of Wisconsin versus Celsior solutions. Transplant Proc 2006, 38.
89. Baertschiger RM, Berney T, Morel P. Organ preservation in pancreas and islet transplantation. Curr Opin Organ Transplant 2008, 13:59.